Barchart.com
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Virios Therapeutics Inc (VIRI)

Virios Therapeutics Inc (VIRI)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1550 +0.0171 (+12.40%) 10/08/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.1550 unch (unch) -
News & Headlines for Tue, Oct 8th, 2024
Help
Go To:
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) GlobeNewswire - Mon Oct 7, 2024

VIRI : 0.1550 (+12.40%)
DWTX : 3.00 (+0.33%)
Author
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal MarketBeat - Tue Apr 25, 2023

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia

VIRI : 0.1550 (+12.40%)
AGN : 193.02 (+0.02%)
LLY : 754.35 (+3.00%)
GPS : 24.55 (+4.38%)
PFE : 22.12 (+0.96%)
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase Business Wire - Tue Nov 29, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update Business Wire - Mon Nov 14, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 Business Wire - Thu Nov 3, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics, Inc. Announces Closing of Public Offering Business Wire - Thu Sep 22, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.1550 (+12.40%)
Wall Street - NY Stock Exchange -mHdATQY9fIU-unsplash
Pre-Market Brief: Stocks Mixed Ahead Of FOMC Meeting Barchart - Tue Sep 20, 2022

December S&P 500 futures (ESZ22) are moderately down -0.08% this morning after three major US benchmark indices rebounded from 9-week lows to close higher during the regular session as market participants...

CGNX : 24.45 (+2.09%)
CHNG : 27.49 (+0.26%)
VIRI : 0.1550 (+12.40%)
F : 9.71 (+4.07%)
GM : 45.14 (+3.46%)
ENVX : 6.01 (+0.50%)
UNH : 587.06 (-2.07%)
ESZ22 : 3,871.47s (-0.66%)
Virios Therapeutics, Inc. Announces Pricing of Public Offering Business Wire - Mon Sep 19, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics, Inc. Announces Proposed Public Offering Business Wire - Mon Sep 19, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.1550 (+12.40%)
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia Business Wire - Mon Sep 19, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.1550 (+12.40%)

Barchart Exclusives

Should You Buy Bitcoin Now? This Wall Street Pro Thinks So Barchart - 12 minutes ago
Bitcoin has been consolidating amidst an emerging trade war in recent weeks. BlackRock’s Larry Fink remains bullish as ever on BTC. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot